DSpace About DSpace Software 日本語
 

GINMU >
01 奈良県立医科大学 >
011 医学部 >
0112 紀要 >
01121 Journal of Nara Medical Association >
Vol.60 No.3-4 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/1090

Title: ADJUVANT CHEMOTHERAPY WITH CISPLATIN / CYCLOPHOSPHAMIDE / DOXORUBICIN FOR PATIENTS WITH UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT
Authors: Chihara, Yosmtomo
Fujimoto, Kiyohide
Miyake, Makito
Anai, Satoshi
Hirayama, Akihide
Keywords: upper urmary tract
urothelial carcinoma
adjuvant chemotherapy
Issue Date: 31-Aug-2009
Publisher: 奈良医学会
奈良県立医科大学
Citation: Journal of Nara Medical Association Vol.60 No.3-4 p.93-102
Abstract: Background Urothelial carcinoma of the upper urinary tract is relatively uncommon and the benefit of adjuvant chemotherapy has not yet been established. We evaluated the efficacy of adjuvant chemotherapy after radical surgery for patients with primary urothelial carcinoma of the renal pelvis and ureter in a randomized controlled trial. Methods Forty patients who underwent radical surgery for localized and locally-invasive upper urinary tract carcinoma without metastasis were randomly assigned to two groups treated with and without adjuvant chemotherapy using cisplatin, cyclophosphamide and doxorubicin (CISCA) to compare the overall, cancer-specific, and recurrence-free survivals between them. UFT was administered orally at a dose of 200-400 mg/day to both groups for 2 years after surgery. Results The median follow-up was 80.5 months. The overall survival and cancer-specific survival rates showed no significant differences (P=0.61 and P=O.28, respectively) between the two groups. The 10-year recurrence-free survival rates also showed no difference between the 2 groups treated with and without adjuvant chemotherapy (68.8% and 54.4%, respectively, P=0.20). All recurrent cases showed recurrence of non-muscle invasive bladder cancer, and thereafter only one patient progressed with distant metastasis. The morbidity of recurrence, particularly within 2 years, and the total number of recurrences tended to be smaller in the adjuvant chemotherapy group than in the non-adjuvant chemotherapy group (P<0.063). Conclusion Adjuvant chemotherapy with CISCA after radical surgery showed no significant survival benefit for the patients with localized and locally-invasive urothelial carcinoma of the upper urinary tract while recurrence of bladder cancer decreased significantly in the adjuvant chemotherapy group compared to the non-adjuvant group.
URI: http://hdl.handle.net/10564/1090
ISSN: 13450069
Appears in Collections:Vol.60 No.3-4

Files in This Item:

File Description SizeFormat
093-102p.ADJUVANT_CHEMOTHERAPY_WITH_CISPLATINCYCLOPHOSPHAMIDEDOXORUBICIN.pdf940.62 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback